Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

After its recent price appreciation, Madrigal Pharmaceuticals (NASDAQ: MDGL ) still justifies a “Buy” rating. It’s encouraging clinical progress and market potential through Resmetirom (Rezdiffra), which seems to be just getting started. MDGL’s stock has rapidly appreciated since my previous article on it, driven by theMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer sc ...